AU2023262720A1 - Inhibitors of rock2 - Google Patents
Inhibitors of rock2 Download PDFInfo
- Publication number
- AU2023262720A1 AU2023262720A1 AU2023262720A AU2023262720A AU2023262720A1 AU 2023262720 A1 AU2023262720 A1 AU 2023262720A1 AU 2023262720 A AU2023262720 A AU 2023262720A AU 2023262720 A AU2023262720 A AU 2023262720A AU 2023262720 A1 AU2023262720 A1 AU 2023262720A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- group
- alkynyl
- alkenyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263336667P | 2022-04-29 | 2022-04-29 | |
| US63/336,667 | 2022-04-29 | ||
| PCT/IB2023/054494 WO2023209692A1 (en) | 2022-04-29 | 2023-04-29 | Inhibitors of rock2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023262720A1 true AU2023262720A1 (en) | 2024-12-12 |
Family
ID=86604437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023262720A Pending AU2023262720A1 (en) | 2022-04-29 | 2023-04-29 | Inhibitors of rock2 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250289807A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4514466A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025514382A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250019030A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119604496A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023262720A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3250707A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316616A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023209692A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026502949A (ja) | 2022-12-30 | 2026-01-27 | アヴィセンナ バイオサイエンシズ インコーポレイテッド | アザインドールrock阻害剤 |
| IL327381A (en) | 2023-09-28 | 2026-05-01 | Graviton Pharmaceuticals B V | Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors |
| IL327385A (en) | 2023-09-29 | 2026-05-01 | Graviton Pharmaceuticals B V | ROCK2 inhibitors in the treatment of obesity |
| WO2026011129A1 (en) * | 2024-07-03 | 2026-01-08 | Avicenna Biosciences, Inc. | Azaindole rock inhibitors for the treatment of medical disorders |
| CN120204259B (zh) * | 2025-04-17 | 2025-11-18 | 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) | Rock2抑制剂及其在制备治疗胆管癌的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7311228B2 (ja) | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| JP7399848B2 (ja) * | 2017-09-01 | 2023-12-18 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | Rho関連コイルドコイル含有プロテインキナーゼの阻害剤 |
-
2023
- 2023-04-29 US US18/861,104 patent/US20250289807A1/en active Pending
- 2023-04-29 JP JP2024563854A patent/JP2025514382A/ja active Pending
- 2023-04-29 IL IL316616A patent/IL316616A/en unknown
- 2023-04-29 CA CA3250707A patent/CA3250707A1/en active Pending
- 2023-04-29 EP EP23726610.1A patent/EP4514466A1/en active Pending
- 2023-04-29 AU AU2023262720A patent/AU2023262720A1/en active Pending
- 2023-04-29 CN CN202380050515.XA patent/CN119604496A/zh active Pending
- 2023-04-29 WO PCT/IB2023/054494 patent/WO2023209692A1/en not_active Ceased
- 2023-04-29 KR KR1020247038811A patent/KR20250019030A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023209692A1 (en) | 2023-11-02 |
| CN119604496A (zh) | 2025-03-11 |
| JP2025514382A (ja) | 2025-05-02 |
| KR20250019030A (ko) | 2025-02-07 |
| US20250289807A1 (en) | 2025-09-18 |
| CA3250707A1 (en) | 2023-11-02 |
| IL316616A (en) | 2024-12-01 |
| EP4514466A1 (en) | 2025-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250289807A1 (en) | Inhibitors of ROCK2 | |
| EP4622973A1 (en) | Inhibitors of rock2 | |
| AU2018222073B2 (en) | O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof | |
| WO2024193439A1 (zh) | Shp2磷酸酶变构抑制剂 | |
| EP2978752B1 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
| CN117143107A (zh) | 1,2-二氢吡啶类衍生物及其制备方法和用途 | |
| JP2020532549A (ja) | Rho関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| US10472349B2 (en) | Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof | |
| AU2012328167A1 (en) | New compounds | |
| EP3418277B1 (en) | Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof | |
| KR20240150493A (ko) | 화합물 및 그 용도 | |
| AU2024208947A1 (en) | Prmt5-mta inhibitor | |
| CN114599655B (zh) | 咪唑烷酮类化合物及其制备方法与应用 | |
| KR20260023568A (ko) | Enpp1 억제제의 결정형 | |
| CN120457116A (zh) | Shp2抑制剂、组合物及其制备方法 | |
| KR20250051688A (ko) | TGF-β 억제제 화합물 및 그 사용 | |
| AU2023366352A1 (en) | New inhibitors of phosphatidylinositol 3-kinase | |
| CN111377906B (zh) | 取代的吡嗪化合物及其制备方法和用途 | |
| WO2025119352A1 (zh) | 一种并环类mat2a抑制剂、包含其的药物组合物及其应用 | |
| JP2021523194A (ja) | インドリン−1−カルボキサミド化合物、そのための調製方法及びその医学的使用 | |
| HK1217701B (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors |